176 related articles for article (PubMed ID: 25280519)
1. EZH2 elevates the proliferation of human cholangiocarcinoma cells through the downregulation of RUNX3.
Tang B; Du J; Li Y; Tang F; Wang Z; He S
Med Oncol; 2014 Nov; 31(11):271. PubMed ID: 25280519
[TBL] [Abstract][Full Text] [Related]
2. Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis.
Nakagawa S; Okabe H; Sakamoto Y; Hayashi H; Hashimoto D; Yokoyama N; Sakamoto K; Kuroki H; Mima K; Nitta H; Imai K; Chikamoto A; Watanabe M; Beppu T; Baba H
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S667-75. PubMed ID: 23887863
[TBL] [Abstract][Full Text] [Related]
3. MiR-124 induces autophagy-related cell death in cholangiocarcinoma cells through direct targeting of the EZH2-STAT3 signaling axis.
Ma J; Weng L; Wang Z; Jia Y; Liu B; Wu S; Cao Y; Sun X; Yin X; Shang M; Mao A
Exp Cell Res; 2018 May; 366(2):103-113. PubMed ID: 29530475
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of enhancer of zeste homolog 2 and MUC1 may be related to malignant behaviour in intraductal papillary neoplasm of the bile duct.
Sasaki M; Matsubara T; Yoneda N; Nomoto K; Tsuneyama K; Sato Y; Nakanuma Y
Histopathology; 2013 Feb; 62(3):446-57. PubMed ID: 23163606
[TBL] [Abstract][Full Text] [Related]
5. An immunohistochemical panel of insulin-like growth factor II mRNA-binding protein 3 (IMP3), enhancer of zeste homolog 2 (EZH2), and p53 is useful for a diagnosis in bile duct biopsy.
Sasaki M; Sato Y
Virchows Arch; 2021 Oct; 479(4):697-703. PubMed ID: 34115196
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells.
Nakagawa S; Sakamoto Y; Okabe H; Hayashi H; Hashimoto D; Yokoyama N; Tokunaga R; Sakamoto K; Kuroki H; Mima K; Beppu T; Baba H
Oncol Rep; 2014 Feb; 31(2):983-8. PubMed ID: 24337160
[TBL] [Abstract][Full Text] [Related]
7. Targeting polycomb repressor complex 2-mediated bivalent promoter epigenetic silencing of secreted frizzled-related protein 1 inhibits cholangiocarcinoma progression.
Wu G; Wang Q; Wang D; Xiong F; Liu W; Chen J; Wang B; Huang W; Wang X; Chen Y
Clin Transl Med; 2023 Dec; 13(12):e1502. PubMed ID: 38050190
[TBL] [Abstract][Full Text] [Related]
8. Enhancer of zeste homolog 2 (EZH2) regulates tumor angiogenesis and predicts recurrence and prognosis of intrahepatic cholangiocarcinoma.
Nakagawa S; Okabe H; Ouchi M; Tokunaga R; Umezaki N; Higashi T; Kaida T; Arima K; Kitano Y; Kuroki H; Mima K; Nitta H; Imai K; Hashimoto D; Yamashita YI; Chikamoto A; Baba H
HPB (Oxford); 2018 Oct; 20(10):939-948. PubMed ID: 29759640
[TBL] [Abstract][Full Text] [Related]
9. Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation.
Fujii S; Ito K; Ito Y; Ochiai A
J Biol Chem; 2008 Jun; 283(25):17324-32. PubMed ID: 18430739
[TBL] [Abstract][Full Text] [Related]
10. Over-expression of polycomb group protein EZH2 relates to decreased expression of p16 INK4a in cholangiocarcinogenesis in hepatolithiasis.
Sasaki M; Yamaguchi J; Itatsu K; Ikeda H; Nakanuma Y
J Pathol; 2008 Jun; 215(2):175-83. PubMed ID: 18393368
[TBL] [Abstract][Full Text] [Related]
11. Immunostaining for polycomb group protein EZH2 and senescent marker p16INK4a may be useful to differentiate cholangiolocellular carcinoma from ductular reaction and bile duct adenoma.
Sasaki M; Matsubara T; Kakuda Y; Sato Y; Nakanuma Y
Am J Surg Pathol; 2014 Mar; 38(3):364-9. PubMed ID: 24487593
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of polycomb repressive complex 2 key components EZH2/SUZ12/EED as an unfavorable prognostic marker in cholangiocarcinoma.
Wasenang W; Puapairoj A; Settasatian C; Proungvitaya S; Limpaiboon T
Pathol Res Pract; 2019 Jul; 215(7):152451. PubMed ID: 31126817
[TBL] [Abstract][Full Text] [Related]
13. The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma.
Sasaki M; Ikeda H; Itatsu K; Yamaguchi J; Sawada S; Minato H; Ohta T; Nakanuma Y
Lab Invest; 2008 Aug; 88(8):873-82. PubMed ID: 18591938
[TBL] [Abstract][Full Text] [Related]
14. EYA4 gene functions as a prognostic marker and inhibits the growth of intrahepatic cholangiocarcinoma.
Hao XY; Cai JP; Liu X; Chen W; Hou X; Chen D; Lai JM; Liang LJ; Yin XY
Chin J Cancer; 2016 Jul; 35(1):70. PubMed ID: 27469137
[TBL] [Abstract][Full Text] [Related]
15. Autocrine parathyroid hormone-like hormone promotes intrahepatic cholangiocarcinoma cell proliferation via increased ERK/JNK-ATF2-cyclinD1 signaling.
Tang J; Liao Y; He S; Shi J; Peng L; Xu X; Xie F; Diao N; Huang J; Xie Q; Lin C; Luo X; Liao K; Ma J; Li J; Zhou D; Li Z; Xu J; Zhong C; Wang G; Bai L
J Transl Med; 2017 Nov; 15(1):238. PubMed ID: 29178939
[TBL] [Abstract][Full Text] [Related]
16. Hepatocyte nuclear factor 6 inhibits the growth and metastasis of cholangiocarcinoma cells by regulating miR-122.
Zhu H; Mi Y; Jiang X; Zhou X; Li R; Wei Z; Jiang H; Lu J; Sun X
J Cancer Res Clin Oncol; 2016 May; 142(5):969-80. PubMed ID: 26825606
[TBL] [Abstract][Full Text] [Related]
17. The role of EZH2 and DNA methylation in the silencing of the tumour suppressor RUNX3 in colorectal cancer.
Kodach LL; Jacobs RJ; Heijmans J; van Noesel CJ; Langers AM; Verspaget HW; Hommes DW; Offerhaus GJ; van den Brink GR; Hardwick JC
Carcinogenesis; 2010 Sep; 31(9):1567-75. PubMed ID: 20631058
[TBL] [Abstract][Full Text] [Related]
18. LncRNA MT1JP plays a protective role in intrahepatic cholangiocarcinoma by regulating miR-18a-5p/FBP1 axis.
Zhao W; Zhao J; Guo X; Feng Y; Zhang B; Tian L
BMC Cancer; 2021 Feb; 21(1):142. PubMed ID: 33557774
[TBL] [Abstract][Full Text] [Related]
19. EZH2 promotes cell proliferation by regulating the expression of RUNX3 in laryngeal carcinoma.
Lian R; Ma H; Wu Z; Zhang G; Jiao L; Miao W; Jin Q; Li R; Chen P; Shi H; Yu W
Mol Cell Biochem; 2018 Feb; 439(1-2):35-43. PubMed ID: 28795320
[TBL] [Abstract][Full Text] [Related]
20. Endothelin inhibits cholangiocarcinoma growth by a decrease in the vascular endothelial growth factor expression.
Fava G; Demorrow S; Gaudio E; Franchitto A; Onori P; Carpino G; Glaser S; Francis H; Coufal M; Marucci L; Alvaro D; Marzioni M; Horst T; Mancinelli R; Benedetti A; Alpini G
Liver Int; 2009 Aug; 29(7):1031-42. PubMed ID: 19291182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
